E-LIB Suche - Ergebnisse für: Davignon, Philip

1

State Medical Boards' Perceptions of a Minimum Data Set and..:

Young, Aaron ; Davignon, Philip ; Hansen, Margaret B..
Journal of Medical Regulation. 99 (2013) 4 - p. 40-45 , 2013

2

Single and Composite Endpoints of Within-Patient Improvemen..:

Schnitzer, Thomas J. ; Berenbaum, Francis ; Conaghan, Philip G....
Rheumatology and Therapy. 8 (2021) 4 - p. 1759-1774 , 2021

Link: https://doi.org/10.1007/..

3

Residual macrovascular risk in 2013: what have we learned?:

for the Residual Risk Reduction Initiative (R3i) ; Fruchart, Jean-Charles ; Davignon, Jean...
Cardiovascular Diabetology. 13 (2014) 1 - p. , 2014

Link: https://doi.org/10.1186/..

4

Comparative efficacy and safety of pravastatin, nicotinic a..:

Davignon, Jean ; Roederer, Ghislaine ; Montigny, Martine...
The American Journal of Cardiology. 73 (1994) 5 - p. 339-345 , 1994

Link: https://doi.org/10.1016/..

5

CD3 expression, modulation and signalling in T-cell subpopu..:

Davignon, Jean-Luc ; Arnold, Larry W. ; Cohen, Philip L..
Journal of Autoimmunity. 4 (1991) 6 - p. 831-844 , 1991

Link: https://doi.org/10.1016/..

6

Immunological effects of recombinant interferon gamma in vi..:

Davignon, Jean-Luc ; Cohen, Philip L. ; Eisenberg, Robert A.
International Journal of Immunopharmacology. 12 (1990) 6 - p. 691-698 , 1990

Link: https://doi.org/10.1016/..

7

Single and Composite Endpoints of Within-Patient Improvemen..:

Schnitzer, Thomas, J ; Berenbaum, Francis ; Conaghan, Philip, G...
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40744-021-00372-2. , 2021

Link: https://hal.sorbonne-uni..

8

Single and Composite Endpoints of Within-Patient Improvemen..:

Schnitzer, Thomas ; Berenbaum, Francis ; Conaghan, Philip...
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40744-021-00372-2. , 2021

Link: https://hal.sorbonne-uni..

9

Single and Composite Endpoints of Within-Patient Improvemen..:

Schnitzer, Thomas J ; Berenbaum, Francis ; Conaghan, Philip G...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572276/. , 2021

Link: http://www.ncbi.nlm.nih...

10

Single and Composite Endpoints of Within-Patient Improvemen..:

Schnitzer, Thomas, J ; Berenbaum, Francis ; Conaghan, Philip, G...
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40744-021-00372-2. , 2021

Link: https://hal.sorbonne-uni..

11

Residual Microvascular Risk in Type 2 Diabetes in 2014: Is ..:

Reiner, Zeljko ; Hu, Dayi ; Gotto, Antonio M...
c4232bc0-a5d9-42e3-aa02-553d77fe3e9d. , 2014

Link: https://doi.org/10.4172/..

12

Residual macrovascular risk in 2013: what have we learned?:

Fruchart, Jean-Charles ; Davignon, Jean ; Hermans, Michel P...
http://www.cardiab.com/content/13/1/26. , 2014

Link: http://www.cardiab.com/c..

13

Residual macrovascular risk in 2013: what have we learned?:

Fruchart, Jean-Charles ; Davignon, Jean ; Hermans, Michel...
https://doi.org/10.7916/D8BV7F51. , 2014

Link: https://doi.org/10.7916/..

14

Residual macrovascular risk in 2013: what have we learned?:

Fruchart, Jean-Charles ; Davignon, Jean ; Hermans, Michael P...
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/11754. , 2014

Link: https://opus.bibliothek...

15

Residual macrovascular risk in 2013: what have we learned?:

Fruchart, Jean-Charles ; Davignon, Jean ; Hermans, Michel...
boreal:161283. , 2014

Link: http://hdl.handle.net/20..